The Development in cancer therapy has brought about treatment approaches that aim to tackle diseases at the cellular level. One of these treatment options involves the use of hypomethylating agents, such as Azacitidine. It has a major significance in the management of various blood conditions such as MDS and AML.
What Are Myelodysplastic Syndromes (MDS)?
Myelodysplastic syndromes (MDS) refer to a set of conditions that are as a result of abnormal formation or functioning of blood cells within the bone marrow. The following points define MDS:
- Bone marrow fails to make sufficient numbers of normal blood cells.
- Blood cells do not work properly.
- Leukemia is a possibility.
The disease is common in older adults and require long term treatment to control symptoms and slow disease progression.
What Is Acute Myeloid Leukemia (AML)?
Acute myeloid leukemia (AML) is a rapidly growing cancer of the blood and bone marrow. This leads to a buildup of abnormal white blood cells that affect the formation of normal blood cells. AML needs immediate treatment and can be either a primary cancer or evolve from pre-existing disorders such as MDS.
What Is Azacitidine?
The therapy is one of the chemotherapy medicines, which falls under the category of hypomethylating agents. It is commonly used to treat specific cancers and bone marrow diseases such as MDS and AML. This medicine can be taken on a continuous basis or with the guidance of a physician.
How Does The Medicine Work?
This medication functions through altering the process of DNA methylation, which is a biological activity that regulates the activation or deactivation of genes within the body. Through manipulation of such process, it enables the restoration of the function of genes that regulate cell growth and development. It facilitates the production of healthy cells and minimizes the proliferation of the abnormal cells. It has an advantage over other treatments since it offers a more specific treatment of diseases.
In Which Conditions Is The TherapyUsed?
The medication is used in cases where:
- Myelodysplastic syndromes (MDS) prevail.
- Acute myeloid leukemia (AML) in selected cases.
- Bones marrow disorder causing improper cell production.
Use of Azacitidine will depend on the severity of the condition and the state of the patient’s body.
What Are the Benefits of The Therapy?
The use of the medicine can provide several advatages, including:
- Increase in blood cells.
- No need for blood transfusion.
- Slow down of disease process.
- Survival advantages in some patients.
It is especially beneficial to those patients who cannot undergo chemotherapy.
What Are the Possible Side Effects?
Like all other cancer therapies, this medicine also cause certain side effects which could vary from person to person, such as:
- Nausea and vomiting
- Fatigue
- Low blood cell counts
- Injection site reactions
- Infections due to low immunity
- Bleeding complications
- Severe anemia
Patient must visit the doctor if they experience any severe or persistent symptoms.
Which Brands Of The Medicine Are Available?
There are several forms of the drug that go by various brand names, these are:
- AZALPHO 100 mg
- VIDAZA 100 mg
The choice of brand depends on the physician and the availability of the drug in the market.
Why Is Monitoring Important During Treatment?
Monitoring will ensure that the medication is not only safe but also efficacious. The following tests may be suggested by doctors:
- Complete blood count (CBC)
- Liver and kidney function test
- Clinical evaluation
How Does Azacitidine Interact with Other Medicines?
It may have interactions with some combination of medications, affecting its efficacy or posing more risks. These may include:
- Chemotherapy medications
- Immunosuppressants
- Supportive medications
The patient should inform the healthcare professional about all the medications they are using or if they cause any side effects.
Conclusion
The medicine is a vital therapy in the treatment of Myelodysplastic Syndromes and some forms of Acute Myeloid Leukemia through the regulation of cellular mechanisms, which facilitates healthy blood cell formation. Under correct medical supervision, patients will be able to effectively manage their health problems and have a better quality of life.
FAQs
1. Is this treatment a chemotherapeutic medication?
Yes, it is a chemotherapeutic therapy that is not similar to other chemotherapeutic agents; it belongs to a category of drugs called hypomethylating agents.
2. How is the medicine delivered to the patient?
It is normally given via subcutaneous or intravenous injections at the fixed intervals as advised by the doctor.
References
- Sekeres, M. A., & Taylor, J. (2022). Diagnosis and treatment of myelodysplastic syndromes: a review. Jama, 328(9), 872-880. https://pubmed.ncbi.nlm.nih.gov/36066514/
- Estey, E., & Döhner, H. (2006). Acute myeloid leukaemia. The Lancet, 368(9550), 1894-1907. https://europepmc.org/article/med/17126723
- Kaminskas, E., Farrell, A. T., Wang, Y. C., Sridhara, R., & Pazdur, R. (2005). FDA drug approval summary: azacitidine (5-azacytidine, Vidaza™) for injectable suspension. The oncologist, 10(3), 176-182. https://pubmed.ncbi.nlm.nih.gov/15793220/
- Chen, Y., Liu, L., Laille, E., Kumar, G., & Surapaneni, S. (2010). In vitro assessment of cytochrome P450 inhibition and induction potential of azacitidine. Cancer chemotherapy and pharmacology, 65(5), 995-1000.
- Glover, A. B., & Leyland-Jones, B. (1987). Biochemistry of Azacitidine: A Review¹. Cancer treatment reports, 71(10-12), 959. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/50-794_Vidaza_Pharmr_P1.pdf
